 The FDA approved the Investigational Device Exemption for Neovasc Incs NASDAQ:NVCN COSIRA-II IDE Clinical Trial regarding the Neovasc Reducer. Related Content: Real-World Study Shows Neovascs Reducer Is Safe, Efficacious In Patients With Refractory Angina. 